These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28115111)

  • 1. FRMD4A/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    Velcheti V; Thawani R; Khunger M; Mukhopadhyay S; Chute DJ; Schrock AB; Ali SM
    J Thorac Oncol; 2017 Feb; 12(2):e15-e16. PubMed ID: 28115111
    [No Abstract]   [Full Text] [Related]  

  • 2. WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    Velcheti V; Madison R; Ali SM; Schrock AB
    J Thorac Oncol; 2018 Jul; 13(7):e122-e123. PubMed ID: 29935851
    [No Abstract]   [Full Text] [Related]  

  • 3. A Novel Oncogenic RET Fusion Variant in Non-Small Cell Lung Cancer: RELCH-RET.
    Jiang H; Xiao M; Qi C; Cai S; Liu F
    J Thorac Oncol; 2020 Feb; 15(2):e27-e28. PubMed ID: 32127187
    [No Abstract]   [Full Text] [Related]  

  • 4. A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET.
    Myrand SP
    J Thorac Oncol; 2021 Oct; 16(10):e95. PubMed ID: 34561049
    [No Abstract]   [Full Text] [Related]  

  • 5. [The progress of KIF5B-RET fusion gene in non-small cell lung cancer].
    Jin LL; Kong H; Xie WP
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul; 36(7):524-6. PubMed ID: 24262090
    [No Abstract]   [Full Text] [Related]  

  • 6. RET fusion genes in non-small-cell lung cancer.
    Chao BH; Briesewitz R; Villalona-Calero MA
    J Clin Oncol; 2012 Dec; 30(35):4439-41. PubMed ID: 23150705
    [No Abstract]   [Full Text] [Related]  

  • 7. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
    Wijesinghe P; Bepler G; Bollig-Fischer A
    J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene fusion implicated in lung cancer occurrence.
    Hadjivasiliou A
    Expert Rev Proteomics; 2012; 9(1):6. PubMed ID: 22397022
    [No Abstract]   [Full Text] [Related]  

  • 9. Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
    Dagogo-Jack I; Stevens SE; Lin JJ; Nagy R; Ferris L; Shaw AT; Gainor JF
    J Thorac Oncol; 2018 Nov; 13(11):e226-e227. PubMed ID: 30368414
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report.
    Xu X; Wang H; Yu Z; Chen X
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1825-1827. PubMed ID: 35364706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.
    Wright KM
    Oncology (Williston Park); 2020 Oct; 34(10):406-406;431. PubMed ID: 33058106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
    Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
    Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
    J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Tan L; Solomon BJ
    Ann Oncol; 2020 Dec; 31(12):1599-1600. PubMed ID: 33045324
    [No Abstract]   [Full Text] [Related]  

  • 16. [Significances of RET fusion gene in non-small cell lung cancer].
    Liu J; Bi M
    Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):615-20. PubMed ID: 24229630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
    Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
    J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Zhang Q; Xu C; Wang W; Wu M; Zhu Y; Zhuang W; Du K; Huang Y; Chen Y; Wu B
    Med Sci Monit; 2018 Nov; 24():8207-8212. PubMed ID: 30429449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expert consensus on clinical practice of RET fusion detection in non-small cell lung cancer in China].
    ; ;
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):583-591. PubMed ID: 34078044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.